Januvia has been accepted for standard review by the Food and Drug Administration, Merck & Co announced in a press statement referring to the February 16, 2006 approval on the new formulation. The company’s investigational medicine for type 2 diabetes was made the first in a new class of oral medications in the United States and planned to be the first one across the world according to www.drugs.com. An oral inhibitor for the treatment of type 2 diabetes, Januvia represents a new and different approach — right now subject of questions raised by some Januvia lawyers because of its side effects reported in clinical studies.

Type 2 diabetes is a condition that shows an increase of blood sugar or glucose. With this condition, the body may not produce enough insulin that helps the body break down glucose. Thus, an inhibitor like Januvia may prevent all these adverse side effects because it enhances the body’s own ability to control blood sugar levels by increasing levels of the incretin hormones that helps in decreasing blood sugar levels in patients with type 2 diabetes.

Finally, with millions of people of type 2 diabetes patients worldwide, Januvia may just be the hope and relief that can stop the epidemic of this atrocious disease.

Source:

fda.gov